RET proto-oncogene: A review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors

Thyroid

Volumn 15, Issue 6, 2005, Pages 531-544

  Kouvaraki, Maria A ^a   Shapiro, Suzanne E ^a   Perrier, Nancy D ^a   Cote, Gilbert J ^a   Gagel, Robert F ^a   Hoff, Ana O ^a   Sherman, Steven I ^a   Lee, Jeffrey E ^a   Evans, Douglas B ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALECTOMY; CANCER SURVIVAL; ENDOCRINE TUMOR; FAMILIAL CANCER; GENE MUTATION; GENOTYPE PHENOTYPE CORRELATION; HUMAN; HYPERPARATHYROIDISM; MULTIPLE ENDOCRINE NEOPLASIA; NEUROFIBROMATOSIS; ONCOGENE RET; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SIPPLE SYNDROME; SOMATIC MUTATION; THYROID CANCER; THYROID MEDULLARY CARCINOMA; THYROIDECTOMY;

CARCINOMA, MEDULLARY; ENDOCRINE GLAND NEOPLASMS; GENOTYPE; HUMANS; PHENOTYPE; PROTO-ONCOGENE PROTEINS C-RET; THYROID NEOPLASMS;

EID: 22244480355     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/thy.2005.15.531     Document Type: Review

References (149)

1. Hazard JB, Hawk WA, Crue G, Jr 1959 Medullary (solid) carcinoma of the thyroid; a clinicopathologic entity. J Clin Endocrinol Metab 19:152-161.
2. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ, Thun MJ, American Cancer Society 2004 Cancer Statistics, 2004. CA Cancer J Clin 54:8-29.
3. Kebebew E, Ituarte PH, Siperstein AE, Duh QY, Clark OH 2000 Medullary thyroid carcinoma: Clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer 88:1139-1148.
4. Gilliland FD, Hunt WC, Morris DM, Key CR 1997 Prognostic factors for thyroid carcinoma. A population-based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) program 1973-1991. Cancer 79:564-573.
5. Block MA, Jackson CE, Greenawald KA, Yott JB, Tashjian AH, Jr 1980 Clinical characteristics distinguishing hereditary from sporadic medullary thyroid carcinoma. Treatment implications. Arch Surg 115:142-148.
6. Mulligan LM, Kwok JB, Healey CS, Elsdon MJ, Eng C, Gardner E, Love DR, Mole SE, Moore JK, Papi L, et al 1993 Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 363:458-460.
7. Donis-Keller H, Dou S, Chi D, Carlson KM, Toshima K, Lairmore TG, Howe JR, Moley JF, Goodfellow P, Wells SA Jr 1993 Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet 2:851-856.
8. Online Mendelian Inheritance in Man, OMIM (TM). Johns Hopkins University, Baltimore, MD. MIM Number: #171400: Date last edited: September 11, 2003. www.ncbi. nlm.nih.gov/omim (Last accessed April 15, 2005).
9. Brandi ML, Gagel RF, Angeli A, Bilezikian JP, Beck-Peccoz P, Bordi C, Conte-Devolx B, Falchelti A, Gheri RG, Libroia A, Lips CJ, Lombardi G, Mannelli M, Pacini F, Ponder BA, Raue F, Skoaseia B, Tamburrano G, Thakker RV, Thompson NW, Tomassitti P, Tonelli F, Wells SA Jr, Marx SJ 2001 Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 86:5658-5671.
10. Eng C, Clayton D, Schuffenecker I, Lenoir G, Cote G, Gagel RF, van Amstel HK, Lips CJ, Nishisho I, Takai SI, Marsh DJ, Robinson BG, Frank-Ranek, Raue F, Xue F, Noll WW, Romei C, Pacini F, Fink M, Niederle B, Zederius J, Nordenskjold M, Komminoth P, Hendy GN, Mulligan LM, et al 1996 The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. Jama 276:1575-1579.
11. Sipple J 1961 The association of pheochromocytoma with carcinomas of the thyroid gland. Am J Med 31:163-166.
12. Steiner AL, Goodman AD, Powers SR 1968 Study of a kindred with pheochromocytoma, medullary thyroid carcinoma, hyperparathyroidism and Cushing's disease: Multiple endocrine neoplasia, type 2. Medicine (Baltimore) 47:371-409.
13. Ponder BA, Ponder MA, Coffey R, Pembrey ME, Gagel RF, Telenius-Berg M, Semple P, Easton DP 1988 Risk estimation and screening in families of patients with medullary thyroid carcinoma. Lancet 1:397-401.
14. Easton DF, Ponder MA, Cummings T, Gagel RF, Hansen HH, Ruchlin S, Tashjian AH Jr, Telenius-Berg M, Ponder BA 1989 The clinical and screening age-at-onset distribution for the MEN-2 syndrome. Am J Hum Genet 44:208-215.
15. Landsvater RM, Rombouts AG, te Meerman GJ, Schilhornvan Veen JM, Berends MJ, Geerdink RA, Struyorenberg A, Buys CH, Lips CJ 1993 The clinical implications of a positive calcitonin test for C-cell hyperplasia in genetically unaffected members of an MEN2A kindred. Am J Hum Genet 52:335-342.
16. Lips CJ, Landsvater RM, Hoppener JW, Geerdink RA, Blijham G, van Veen JM, van Gils AP, de Wit MJ, Zewald RA, Berends MJ, et al 1994 Clinical screening as compared with DNA analysis in families with multiple endocrine neoplasia type 2A. N Engl J Med 331:828-835.
17. Eng C, Mulligan LM, Smith DP, Healey CS, Frilling A, Raue F, Neumann HP, Ponder MA, Ponder BA 1995 Low frequency of germline mutations in the RET proto-oncogene in patients with apparently sporadic medullary thyroid carcinoma. Clin Endocrinol (Oxf) 43:123-127.
18. Decker RA, Peacock ML, Watson P 1998 Hirschsprung disease in MEN 2A: Increased spectrum of RET exon 10 genotypes and strong genotype-phenotype correlation. Hum Mol Genet 7:129-134.
19. Gagel RF, Levy ML, Donovan DT, Alford BR, Wheeler T, Tschen JA 1989 Multiple endocrine neoplasia type 2a associated with cutaneous lichen amyloidosis. Ann Intern Med 111:802-806.
20. Gorlin RJ, Sedano HO, Vickers RA, Cervenka J 1968 Multiple mucosal neuromas, pheochromocytoma and medullary carcinoma of the thyroid-A syndrome. Cancer 22:293-299 passim.
21. Koch CA, Pacak K, Chrousos GP 2002 The molecular pathogenesis of hereditary and sporadic adrenocortical and adrenomedullary tumors. J Clin Endocrinol Metab 87:5367-5384.
22. Webb TA, Sheps SG, Carney JA 1980 Differences between sporadic pheochromocytoma and pheochromocytoma in multiple endocrime neoplasia, type 2. Am J Surg Pathol 4:121-126.
23. Inabnet WB, Caragliano P, Pertsemlidis D 2000 Pheochromocytoma: inherited associations, bilaterality, and cortex preservation. Surgery 128:1007-1011;discussion 1011-1002.
24. Neumann HP, Bausch B, McWhinney SR, Bender BU, Gimm O, Franke G, Schipper J, Klisch J, Altehoefer C, Zerres K, Januszewicz A, Eng C, Smith WM, Munk R, Manz T, Glaesker S, Apel TW, Treier M, Reineke M, Walz MK, Hoang-Vu C, Brauckhoff M, Klein-Franke A, Klose P, Schmidt H, Maier-Woelfle M, Peczkowska M, Szmigielski C, Eng C, Freiburg-Warsaw-Columbus Pheochromocytoma Study Group 2002 Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med 346:1459-1466.
25. Conte-Devolx B, Schuffenecker I, Niccoli P, Maes B, Boneu A, Barbot M, Corcuff JB, Murat A, Henry JF, Modigliani E 1997 Multiple endocrine neoplasia type 2: Management of patients and subjects at risk. French Study Group on Calcitonin-Secreting Tumors (GETC). Horm Res 47:221-226.
26. Modigliani E, Vasen HM, Raue K, Dralle H, Frilling A, Gheri RG, Brandi ML, Limbert E, Niederle B, Forgas L, et al 1995 Pheochromocytoma in multiple endocrine neoplasia type 2: European study. The Euromen Study Group. J Intern Med 238:363-367.
27. Eng C 1999 RET proto-oncogene in the development of human cancer. J Clin Oncol 17:380-393.
28. Farndon JR, Leight GS, Dilley WG, Baylin SB, Smallridge RC, Harrison TS, Wells SA Jr 1986 Familial medullary thyroid carcinoma without associated endocrinopathies: A distinct clinical entity. Br J Surg 73:278-281.
29. Sanso GE, Domene HM, Garcia R, Pusiol E, de M Rogue M, Ring A, Perinetti H, Eisner B, Iorcansky S, Barontini M 2002 Very early detection of RET proto-oncogene mutation is crucial for preventive thyroidectomy in multiple endocrine neoplasia type 2 children: Presence of C-cell malignant disease in asymptomatic carriers. Cancer 94: 323-330.
30. Kaufman FR, Roe TF, Isaacs H, Jr, Weitzman JJ 1982 Metastatic medullary thyroid carcinoma in young children with mucosal neuroma syndrome. Pediatrics 70:263-267.
31. Wohllk N, Cote GJ, Evans DB, Goepfert H, Ordonez NG, Gagel RF 1996 Application of genetic screening information to the management of medullary thyroid carcinoma and multiple endocrine neoplasia type 2. Endocrinol Metab Clin North Am 25:1-25.
32. Takahashi M, Ritz J, Cooper GM 1985 Activation of a novel human transforming gene, ret, by DNA rearrangement. Cell 42:581-588.
33. Takahashi M, Buma Y, Iwamoto T, Inaguma Y, Ikeda H, Hiai H 1988 Cloning and expression of the ret proto-oncogene encoding a tyrosine kinase with two potential transmembrane domains. Oncogene 3:571-578.
34. Pachnis V, Mankoo B, Costantini F 1993 Expression of the c-ret proto-oncogene during mouse embryogenesis. Development 119:1005-1017.
35. Tsuzuki T, Takahashi M, Asai N, Iwashita T, Matsuyama M, Asai J 1995 Spatial and temporal expression of the ret proto-oncogene product in embryonic, infant and adult rat tissues. Oncogene 10:191-198.
36. Tahira T, Ishizaka Y, Itoh F, Sugimura T, Nagao M 1990 Characterization of ret proto-oncogene mRNAs encoding two isoforms of the protein product in a human neuroblastoma cell line. Oncogene 5:97-102.
37. Myers SM, Eng C, Ponder BA, Mulligan LM 1995 Characterization of RET proto-oncogene 3′ splicing variants and polyadenylation sites: A novel C-terminus for RET. Oncogene 11:2039-2045.
38. Takahashi M 2001 The GDNF/RET signaling pathway and human diseases. Cytokine Growth Factor Rev 12:361-373.
39. de Graaff E, Srinivas S, Kilkenny C, D'Agati V, Mankou BS, Constantini F, Pachnis V 2001 Differential activities of the RET tyrosine kinase receptor isoforms during mammalian embryogenesis. Genes Dev 15:2433-2444.
40. Lee DC, Chan KW, Chan SY 2002 RET receptor tyrosine kinase isoforms in kidney function and disease. Oncogene 21:5582-5592.
41. Tsui-Pierchala BA, Milbrandt J, Johnson EM, Jr 2002 NGF utilizes c-Ret via a novel GFL-independent, inter-RTK signaling mechanism to maintain the trophic status of mature sympathetic neurons. Neuron 33:261-273.
42. Tsui-Pierchala BA, Ahrens RC, Crowder RJ, Milbrandt J, Johnson EM, Jr 2002 The long and short isoforms of Ret function as independent signaling complexes. J Biol Chem 277:34618-34625.
43. Jing S, Wen D, Yu Y, Holst PL, Luo Y, Fang M, Tamir R, Antonio L, Hu Z, Cupples R, Louis JC, Hu S, Altrock BW, Fox GM 1996 GDNF-induced activation of the ret protein tyrosine kinase is mediated by GDNFR-alpha, a novel receptor for GDNF. Cell 85:1113-1124.
44. Treanor JJ, Goodman L, de Sauvage F, Stone DM, Poulsen KT, Beck CD, Gray C, Armanini MP, Pollock RA, Hefti F, Phillips HS, Goddard A, Moore MW, Buj-Bello A, Davies AM, Asai N, Takahashi M, Vandlen R, Henderson CE, Rosenthal A 1996 Characterization of a multicomponent receptor for GDNF. Nature 382:80-83.
45. Baloh RH, Tansey MG, Lampe PA, Fahrner TJ, Enomoto H, Simburger KS, Leitner ML, Araki T, Johnson EM Jr, Milbranat J 1998 Artemin, a novel member of the GDNF ligand family, supports peripheral and central neurons and signals through the GFRalpha3-RET receptor complex. Neuron 21:1291-1302.
46. Airaksinen MS, Titievsky A, Saarma M 1999 GDNF family neurotrophic factor signaling: Four masters, one servant? Mol Cell Neurosci 13:313-325.
47. Milbrandt J, de Sauvage FJ, Fahrner TJ, Milbrandt J, de Sauvage FJ, Fahrner TJ, Baloh RH, Leitner ML, Tansey MG, Lampe PA, Heuckeroth RO, Kotzbauer PT, Simburger KS, Golden JP, Davies JA, Vejsada R, Kato AC, Hynes M, Sherman D, Nishimura M, Wang LC, Vandlen R, Moffat B, Klein RD, Poulsen K, Gray C, Garces A, Johnson Em Jr, et al 1998 Persephin, a novel neurotrophic factor related to GDNF and neurturin. Neuron 20:245-253.
48. Kotzbauer PT, Lampe PA, Heuckeroth RO, Golden JP, Creedon DJ, Johnson EM, Jr, Milbrandt J 1996 Neurturin, a relative of glial-cell-line-derived neurotrophic factor. Nature 384:467-470.
49. Baloh RH, Enomoto H, Johnson EM, Jr, Milbrandt J 2000 The GDNF family ligands and receptors-implications for neural development. Curr Opin Neurobiol 10:103-110.
50. Sanicola M, Hession C, Worley D, Carmillo P, Ehrenfels C, Walus L, Robinson S, Jaworski G, Wei H, Tizard R, Whitty A, Pepinsky RB, Cate RL 1997 Glial cell line-derived neurotrophic factor-dependent RET activation can be mediated by two different cell-surface accessory proteins. Proc Natl Acad Sci USA 94:6238-6243.
51. Creedon DJ, Tansey MG, Baloh RH, Osborne PA, Lampe PA, Fahrner TJ, Heuckeroth RO, Milbrandt J, Johnson EM Jr 1997 Neurturin shares receptors and signal transduction pathways with glial cell line-derived neurotrophic factor in sympathetic neurons. Proc Natl Acad Sci USA 94:7018-7023.
52. Airaksinen MS, Saarma M 2002 The GDNF family: Signalling, biological functions and therapeutic value. Nat Rev Neurosci 3:383-394.
53. Ohiwa M, Murakami H, Iwashita T, Asai N, Iwata Y, Imai T, Funahashi H, Takagi H, Takahashi M 1997 Characterization of Ret-Shc-Grb2 complex induced by GDNF, MEN 2A, and MEN 2B mutations. Biochem Biophys Res Commun 237:747-751.
54. van Weering DH, Medema JP, van Puijenbroek A, Burgering BM, Baas PD, Bos JL 1995 Ret receptor tyrosine kinase activates extracellular signal-regulated kinase 2 in SK-N-MC cells. Oncogene 11:2207-2214.
55. Worby CA, Vega QC, Zhao Y, Chao HH, Seasholtz AF, Dixon JE 1996 Glial cell line-derived neurotrophic factor signals through the RET receptor and activates mitogen-activated protein kinase. J Biol Chem 271:23619-23622.
56. van Weering DH, Bos JL 1997 Glial cell line-derived neurotrophic factor induces Ret-mediated lamellipodia formation. J Biol Chem 272:249-254.
57. Xing S, Furminger TL, Tong Q, Jhiang SM 1998 Signal transduction pathways activated by RET oncoproteins in PC12 pheochromocytoma cells. J Biol Chem 273:4909-4914.
58. Chiariello M, Visconti R, Carlomagno F, Melillo RM, Bucci C, de Franciscis V, Fox GM, Jing S, Coso OA, Gutkind JS, Fusco A, Santoro M 1998 Signalling of the Ret receptor tyrosine kinase through the c-Jun NH2-terminal protein kinases (JNKS): Evidence for a divergence of the ERKs and JNKs pathways induced by Ret. Oncogene 16:2435-2445.
59. Murakami H, Iwashita T, Asai N, Shimono Y, Iwata Y, Kawai K, Takahashi M 1999 Enhanced phosphatidylinositol 3-kinase activity and high phosphorylation state of its downstream signalling molecules mediated by ret with the MEN 2B mutation. Biochem Biophys Res Commun 262: 68-75.
60. Murakami H, Iwashita T, Asai N, Iwata Y, Narumiya S, Takahashi M 1999 Rho-dependent and -independent tyrosine phosphorylation of focal adhesion kinase, paxillin and p130Cas mediated by Ret kinase. Oncogene 18:1975-1982.
61. Melillo RM, Barone MV, Lupoli G, Cirafici AM, Carlomagno F, Visconti R, Matoskova B, Di Fiore PP, Vecchio G, Fusco A, Santoro M 1999 Ret-mediated mitogenesis requires Src kinase activity. Cancer Res 59:1120-1126.
62. Trupp M, Scott R, Whittemore SR, Ibanez CF 1999 Ret-dependent and -independent mechanisms of glial cell line-derived neurotrophic factor signaling in neuronal cells. J Biol Chem 274:20885-20894.
63. Soler RM, Dolcet X, Encinas M, Egea J, Bayascas JR, Cornelia JX 1999 Receptors of the glial cell line-derived neurotrophic factor family of neurotrophic factors signal cell survival through the phosphatidylinositol 3-kinase pathway in spinal cord motoneurons. J Neurosci 19: 9160-9169.
64. Feng L, Wang CY, Jiang H, Oho C, Dugich-Djordjevic M, Mei L, Lu B 1999 Differential signaling of glial cell line-derived neurothrophic factor and brain-derived neurotrophic factor in cultured ventral mesencephalic neurons. Neuroscience 93:265-273.
65. Hayashi H, Ichihara M, Iwashita T, Murakami H, Shimono Y, Kawai K, Kurokawa K, Murakumo Y, Imai T, Funahashi H, Nakao A, Takahashi M 2000 Characterization of intracellular signals via tyrosine 1062 in RET activated by glial cell line-derived neurotrophic factor. Oncogene 19:4469-4475.
66. Segouffin-Cariou C, Billaud M 2000 Transforming ability of MEN2A-RET requires activation of the phosphatidyl-inositol 3-kinase/AKT signaling pathway. J Biol Chem 275:3568-3576.
67. Ichihara M, Murakumo Y, Takahashi M 2004 RET and neuroendocrine tumors. Cancer Lett 204:197-211.
68. Takahashi M, Iwashita T, Santoro M, Lyonnet S, Lenoir GM, Billaud M 1999 Co-segregation of MEN2 and Hirschsprung's disease: The same mutation of RET with both gain and loss-of-function? Hum Mutat 13:331-336.
69. Donghi R, Sozzi G, Pierotti MA, Biunno I, Miozzo M, Fusco A, Grieco M, Santoro M, Vecchio G, Spurr NK, et al 1989 The oncogene associated with human papillary thyroid carcinoma (PTC) is assigned to chromosome 10 q11-q12 in the same region as multiple endocrine neoplasia type 2A (MEN2A). Oncogene 4:521-523.
70. Grieco M, Santoro M, Berlingieri MT, Melillo RM, Donghi R, Bongarzone I, Pierotti MA, Della Porta G, Fusco A, Vecchio G 1990 PTC is a novel rearranged form of the ret protooncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell 60:557-563.
71. Edery P, Lyonnet S, Mulligan LM, Pelet A, Dow F, Abel L, Holder S, Nihoul-Fekefe C, Ponder BA, Munnich A 1994 Mutations of the RET proto-oncogene in Hirschsprung's disease. Nature 367:378-380.
72. Romeo G, Ronchetto P, Luo Y, Barone V, Seri M, Ceccherini I, Pacini B, Bocciardi R, Lerone M, Kaarianen H, et al 1994 Point mutations affecting the tyrosine kinase domain of the RET proto-oncogene in Hirschsprung's disease. Nature 367:377-378.
73. Angrist M, Bolk S, Thiel B, Puffenberger EG, Hofsrra RM, Buys CH, Cass DT, Chakravarti A 1995 Mutation analysis of the RET receptor tyrosine kinase in Hirschsprung disease. Hum Mol Genet 4:821-830.
74. Attie T, Pelet A, Edery P, Eng C, Mulligan LM, Amiel J, Boutrand L, Beldjord C, Nihoul-Feketi C, Munnich A, et al 1995 Diversity of RET proto-oncogene mutations in familial and sporadic Hirschsprung disease. Hum Mol Genet 4:1381-1386.
75. Eng C 1996 Seminars in medicine of the Beth Israel Hospital, Boston. The RET proto-oncogene in multiple endocrine neoplasia type 2 and Hirschsprung's disease. N Engl J Med 335:943-951.
76. Eng C, Mulligan LM 1997 Mutations of the RET proto-oncogene in the multiple endocrine neoplasia type 2 syndromes, related sporadic rumours, and hirschsprung disease. Hum Mutat 9:97-109.
77. Santoro M, Carlomagno F, Romano A, Bottaro DP, Dathan NA, Gricco M, Fusco A, Vecchio G, Matoskova B, Kraus MH, et al 1995 Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B. Science 267:381-383.
78. Asai N, Iwashita T, Matsuyama M, Takahashi M 1995 Mechanism of activation of the ret proto-oncogene by multiple endocrine neoplasia 2A mutations. Mol Cell Biol 15:1613-1619.
79. Xing S, Smanik PA, Oglesbee MJ, Trosko JE, Mazzaferri EL, Jhiang SM 1996 Characterization of ret oncogenic activation in MEN2 inherited cancer syndromes. Endocrinology 137:1512-1519.
80. Akhand AA, Ikeyama T, Akazawa S, Kato M, Hossain K, Takeda K, Suzuki H, Takahashi M, Nakashima I 2002 Evidence of both extra- and intracellular cysteine targets of protein modification for activation of RET kinase. Biochem Biophys Res Commun 292:826-831.
81. Hofstra RM, Landsvater RM, Ceccherini I, Stulp RP, Stelwagen T, Luo Y, Pasini B, Hoppener JW, van Amstel HK, Romeo G, et al 1994 A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature 367: 375-376.
82. Eng C, Smith DP, Mulligan LM, Healey CS, Zvelebil MJ, Stonehouse TJ, Ponder MA, Jackson CE, Waterfield MD, Ponder BA 1995 A novel point mutation in the tyrosine kinase domain of the RET proto-oncogene in sporadic medullary thyroid carcinoma and in a family with FMTC. Oncogene 10:509-513.
83. Kalinin V, Frilling A 1998 27-bp deletion in the ret protooncogene as a somatic mutation associated with medullary thyroid carcinoma. J Mol Med 76:365-367.
84. Kalinin VN, Amosenko FA, Shabanov MA, Lubchenko LN, Hosch SB, Garkavtseva RF, Izbicki JR 2001 Three novel mutations in the RET proto-oncogene. J Mol Med 79:609-612.
85. Alemi M, Lucas SD, Sallstrom JF, Bergholm U, Akerstrom G, Wilander E 1997 A complex nine base pair deletion in RET exon 11 common in sporadic medullary thyroid carcinoma. Oncogene 14:2041-2045.
86. Chiefari E, Russo D, Giuffrida D, Zampa GA, Meringolo D, Arturi F, Chiodini I, Bianchi D, Attard M, Trischitta V, Bruno R, Giannasio P, Pontecorvi A, Filetti S 1998 Analysis of RET proto-oncogene abnormalities in patients with MEN 2A, MEN 2B, familial or sporadic medullary thyroid carcinoma. J Endocrinol Invest 21:358-364.
87. Eng C, Mulligan LM, Smith DP, Healey CS, Frilling A, Raue F, Neumann HP, Pfragner R, Behmel A, Lorenzo MJ, et al 1995 Mutation of the RET protooncogene in sporadic medullary thyroid carcinoma. Genes Chromosomes Cancer 12:209-212.
88. Marsh DJ, Learoyd DL, Andrew SD, Krishnan L, Pojer R, Richardson AL, Delbridge L, Eng C, Robinson BG 1996 Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinoma. Clin Endocrinol (Oxf) 44: 249-257.
89. Scurini C, Quadro L, Fattoruso O, Verga U, Libroia A, Lupoli G, Cascone E, Marzano L, Paracchi S, Busnardo B, Girelli ME, Bellastella A, Colantuoni V 1998 Germline and somatic mutations of the RET proto-oncogene in apparently sporadic medullary thyroid carcinomas. Mol Cell Endocrinol 137:51-57.
90. Zedenius J, Larsson C, Bergholm U, Bovee J, Svensson A, Hallengren B, Grimelius L, Backdahl M, Weber G, Wallin G 1995 Mutations of codon 918 in the RET proto-oncogene correlate to poor prognosis in sporadic medullary thyroid carcinomas. J Clin Endocrinol Metab 80:3088-3090.
91. Beldjord C, Desclaux-Arramond F, Raffin-Sanson M, Corvol JC, De Keyzer Y, Lutton JP, Plouin PF, Bertagna X 1995 The RET protooncogene in sporadic pheochromocytomas: Frequent MEN 2-like mutations and new molecular defects. J Clin Endocrinol Metab 80:2063-2068.
92. Eng C, Crossey PA, Mulligan LM, Healey CS, Houghton C, Prowse A, Chew SL, Dahia PL, O'Riordan JL, Toledo SP, et al 1995 Mutations in the RET proto-oncogene and the von Hippel-Lindau disease tumour suppressor gene in sporadic and syndromic phaeochromocytomas. J Med Genet 32:934-937.
93. Rodien P, Jeunemaitre X, Dumont C, Beldjord C, Plouin PF 1997 Genetic alterations of the RET proto-oncogene in familial and sporadic pheochromocytomas. Horm Res 47: 263-268.
94. Lindor NM, Honchel R, Khosla S, Thibodeau SN 1995 Mutations in the RET protooncogene in sporadic pheochromocytomas. J Clin Endocrinol Metab 80:627-629.
95. Eng C, Smith DP, Mulligan LM, Nagai MA, Healey CS, Ponder MA, Gardner E, Scheumann GF, Jackson CE, Tunnacliffe A, et al 1994 Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours. Hum Mol Genet 3:237-241.
96. Elisei R, Cosci B, Romei C, Agate L, Piamplani P, Miccoli P, Berti P, Basolo F, Ugolini C, Ciampi R, Nikiforov Y, Pinchera A 2004 Identification of a novel point mutation in the RET gene (Ala883Thr), which is associated with medullary thyroid carcinoma phenotype only in homozygous condition. J Clin Endocrinol Metab 89:5823-5827.
97. McWhinney SR, Boru G, Binkley PK, Peczkowska M, Januszewicz AA, Neumann HP, Eng C 2003 Intronic single nucleotide polymorphisms in the RET protooncogene are associated with a subset of apparently sporadic pheochromocytoma and may modulate age of onset. J Clin Endocrinol Metab 88:4911-4916.
98. Borrego S, Wright FA, Fernandez RM, Williams N, Lopez-Alonso M, Davuluri R, Antinolo G, Eng C 2003 A founding locus within the RET proto-oncogene may account for a large proportion of apparently sporadic Hirschsprung disease and a subset of cases of sporadic medullary thyroid carcinoma. Am J Hum Genet 72:88-100.
99. Griseri P, Pesce B, Patrone G, Orsinga J, Pupo F, Sancandi M, Hofstra R, Romeo G, Ravazzolo R, Devoto M, Ceccherini I 2002 A rare haplotype of the RET proto-oncogene is a risk-modifying allele in hirschsprung disease. Am J Hum Genet 71:969-974.
100. Borrego S, Saez ME, Ruiz A, Gimm O, Lopez-Alonso M, Antinolo G, Eng C 1999 Specific polymorphisms in the RET proto-oncogene are over-represented in patients with Hirschsprung disease and may represent loci modifying phenotypic expression. J Med Genet 36:771-774.
101. Yip L, Cote GJ, Shapiro SE, Ayers GD, Herzog CE, Sellin RV, Sherman SI, Gagel RF, Lee JE, Evans DB 2003 Multiple endocrine neoplasia type 2: evaluation of the genotype-phenotype relationship. Arch Surg 138:409-416; discussion 416.
102. Gagel R, Marx S 2003 Multiple endocrine neoplasia. In: Larsen P, Kronenberg H, Melmed S, et al (eds) Williams Textbook of Endocrinology, 10th ed., Vol 1. Philadelphia, W.B. Saunders, pp. 1717-1762.
103. Mulligan LM, Eng C, Healey CS, Clayton D, Kwok JB, Gardner E, Ponder MA, Frilling A, Jackson CE, Lehnert H, et al 1994 Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC. Nat Genet 6:70-74.
104. Chabre O, Labat F, Pinel N, Berthod F, Tarel V, Bachelot I 1992 Cutaneous lesion associated with multiple endocrine neoplasia type 2A: Lichen amyloidosis or notalgia paresthetica? Henry Ford Hosp Med J 40:245-248.
105. Wong CK, Lin CS 1988 Friction amyloidosis. Int J Dermatol 27:302-307.
106. Raue F, Kraimps JL, Dralle H, Cougard P, Proye C, Frilling A, Limbert E, Llenas LF, Niederle B 1995 Primary hyperparathyroidism in multiple endocrine neoplasia type 2A. J Intern Med 238:369-373.
107. Jimenez C, Dang GT, Schultz PN, El-Naggar A, Shapiro S, Barnes EA, Evans DB, Vassilopoulou-Sellin R, Gagel RF, Cote GJ, Hoff AO 2004 A novel point mutation of the RET protooncogene involving the second intracellular tyrosine kinase domain in a family with medullary thyroid carcinoma. J Clin Endocrinol Metab 89:3521-3526.
108. Bolino A, Schuffenecker I, Luo Y, Seri M, Silengo M, Tocco T, Chabrier G, Houdent C, Murat A, Schlumberger M, et al 1995 RET mutations in exons 13 and 14 of FMTC patients. Oncogene 10:2415-2419.
109. Fink M, Weinhusel A, Niederle B, Haas OA 1996 Distinction between sporadic and hereditary medullary thyroid carcinoma (MTC) by mutation analysis of the RET protooncogene. "Study Group Multiple Endocrine Neoplasia Austria (SMENA)." Int J Cancer 69:312-316.
110. Nilsson O, Tisell LE, Jansson S, Ahlman H, Gimm O, Eng C 1999 Adrenal and extra-adrenal pheochromocytomas in a family with germline RET V804L mutation. JAMA 281:1587-1588.
111. Fattoruso O, Quadro L, Libroia A, Verga U, Lupoli G, Cascone E, Colantuoni V 1998 A GTG to ATG novel point mutation at codon 804 in exon 14 of the RET proto-oncogene in two families affected by familial medullary thyroid carcinoma. Hum Mutat 1:5167-171.
112. Feldman GL, Edmonds MW, Ainsworth PJ, Schuffenecker I, Lenoir GM, Saxe AW, Talpos GB, Roberson J, Petrucelli N, Jackson CE 2000 Variable expressivity of familial medullary thyroid carcinoma (FMTC) due to a RET V804M (GTG > ATG) mutation. Surgery 128:93-98.
113. Smith DP, Houghton C, Ponder BA 1997 Germline mutation of RET codon 883 in two cases of de novo MEN 2B, Oncogene 15:1213-1217.
114. Carlson KM, Dou S, Chi D, Scavarda N, Toshima K, Jackson CE, Wells SA Jr, Goodfellow PJ, Donis-Keller H 1994 Single missense mutation in the tyrosine kinase catalytic domain of the RET protooncogene is associated with multiple endocrine neoplasia type 2B. Proc Natl Acad Sci USA 91:1579-1583.
115. Rossel M, Schuffenecker I, Schlumberger M, Bonnardel C, Modigliani E, GardetP, Navarro J, Luo Y, Romeo G, Lenoir G, et al 1995 Detection of a germline mutation at codon 918 of the RET proto-oncogene in French MEN 2B families. Hum Genet 95:403-406.
116. Jindrichova S, Kodet R, Krskova L, Vlcek P, Bendlova B 2003 The newly detected mutations in the RET proto-oncogene in exon 16 as a cause of sporadic medullary thyroid carcinoma. J Mol Med 81:819-823.
117. Amosenko FA, Brzhezovskiy VZ, Lyubchenko LN, Shabanov MA, Kozlova VM, Vanushko VE, Kazubskaia TP, Gar'kavtseva RF, Kalinin VN 2003 Analysis of mutations of the RET proto-oncogene in patients with medullary thyroid carcinoma [in Russian]. Genetika 39:847-854.
118. Kitamura Y, Scavarda N, Wells SA, Jr, Jackson CE, Goodfellow PJ 1995 Two maternally derived missense mutations in the tyrosine kinase domain of the RET protooncogene in a patient with de novo MEN 2B. Hum Mol Genet 4:1987-1988.
119. Miyauchi A, Futami H, Hai N, Yokozawa T, Kuma K, Aoki N, Kosugi S, Sugano K, Yamaguchi K 1999 Two germline missense mutations at codons 804 and 806 of the RET protooncogene in the same allele in a patient with multiple endocrine neoplasia type 2B without codon 918 mutation. Jpn J Cancer Res 90:1-5.
120. Iwashita T, Murakami H, Kurokawa K, Kawai K, Miyauchi A, Futanni H, Qiao S, Ichihara M, Takahashi M 2000 A two-hit model for development of multiple endocrine neoplasia type 2B by RET mutations. Biochem Biophys Res Commun 268:804-808.
121. Jimenez C, Habra MA, Huang SC, El-Naggar A, Shapiro SE, Evans DB, Cote G, Gagel RF 2004 Pheochromocytoma and medullary thyroid carcinoma: A new genotype-phenotype correlation of the RET protooncogene 891 germline mutation. J Clin Endocrinol Metab 89:4142-4145.
122. Frohnauer MK, Decker RA 2000 Update on the MEN 2A c804 RET mutation: Is prophylactic thyroidectomy indicated? Surgery 128:1052-1057; discussion 1057-1058.
123. Machens A, Niccoli-Sire P, Hoegel J, Frank-Raue K, van Vroonhoven TJ, Roeher HD, Wahl RA, Lamesch P, Raue F, Conte-Devolx B, Dralle H; European Multilpe Endocrine Neoplasia (EUROMEN) Study Group 2003 Early malignant progression of hereditary medullary thyroid cancer. N Engl J Med 349:1517-1525.
124. Greene FL, Page DL, Fleming ID, Fritz A, Balch CM, Haller DG, Morrow M (eds) 2002 AJCC Cancer Staging Manual, 6th ed. Springer-Verlag, New York.
125. Badner JA, Sieber WK, Carver KL, Chakravarti A 1990 A genetic study of Hirschsprung disease. Am J Hum Genet 46:568-580.
126. Fitze G, Cramer J, Ziegler A, Schierz M, Schreiber M, Kuhlisch E, Roesner D, Schackert HK 2002 Association between C135G/A genotype and RET proto-oncogene germline mutations and phenotype of Hirschsprung's disease. Lancet 359:1200-1205.
127. Seri M, Yin L, Barone V, Bolino A, Celli I, Bocciardi R, Pasini B, Ceccherini I, Lerone M, Kristoffersson U, Larsson LT, Casasa JM, Cass DT, Ambramowicz MJ, Vanderwinden JM, Kravcenkiene I, Baric I, Silengo M, Martucciello G, Romeo G 1997 Frequency of RET mutations in long- and short-segment Hirschsprung disease. Hum Mutat 9:243-249.
128. Peretz H, Luboshitsky R, Baron E, Biton A, Gershoni R, Usher S, Goynberg E, Yacobson E, Graff E, Lapidot M 1997 Cys 618 Arg mutation in the RET proto-oncogene associated with familial medullary thyroid carcinoma and maternally transmitted Hirschsprung's disease suggesting a role for imprinting. Hum Mutat 10:155-159.
129. Cohen MS, Phay JE, Albinson C, DeBenedetti MK, Skinner MA, Lairmore TC, Doherty GM, Balfe DM, Wells SA Jr, Moley TF 2002 Gastrointestinal manifestations of multiple endocrine neoplasia type 2. Ann Surg 235:648-654; discussion 654-645.
130. Gabriel SB, Salomon R, Pelet A, Angrist M, Amiel J, Fornage M, Attie-Bitach T, Olson JM, Hofstra R, Buys C, Steffann J, Munnich A, Lyonnet S, Chakravarti A 2002 Segregation at three loci explains familial and population risk in Hifschsprung disease. Nat Genet 31:89-93.
131. Passarge E 2002 Dissecting Hirschsprung disease. Nat Genet 31:11-12.
132. Nishikawa M, Murakumo Y, Imai T, Imai T, Kawai K, Nagaya M, Funahashi H, Nakao A, Takashi M 2003 Cys611Ser mutation in RET proto-oncogene in a kindred with medullary thyroid carcinoma and Hirschsprung's disease. Eur J Hum Genet 11:364-368.
133. Borrego S, Ruiz A, Saez ME, Gimm O, Gao X, Lopez-Alonso M, Hernandez A, Wright FA, Antinolo G, Eng C 2000 RET genotypes comprising specific haplotypes of polymorphic variants predispose to isolated Hirschsprung disease. J Med Genet 37:572-578.
134. Borrego S, Eng C, Sanchez B, Saez ME, Navarro E, Antinolo G 1998 Molecular analysis of the ret and GDNF genes in a family with multiple endocrine neoplasia type 2A and Hirschsprung disease. J Clin Endocrinol Metab 83:3361-3364.
135. Fitze G, Schierz M, Kuhlisch E, Schreiber M, Ziegler A, Roesner D, Schackert HK 2003 Novel intronic polymorphisms in the RET proto-oncogene and their association with Hirschsprung disease. Hum Mutat 22:177.
136. Heshmati HM, Gharib H, van Heerden JA, Sizemore GW 1997 Advances and controversies in the diagnosis and management of medullary thyroid carcinoma. Am J Med 103: 60-69.
137. Vierhapper H, Raber W, Bieglmayer C, Kaserer K, Weinhausl A, Niederle B 1997 Routine measurement of plasma calcitonin in nodular thyroid diseases. J Clin Endocrinol Metab 82:1589-1593.
138. Hennessy JF, Wells SA, Jr, Ontjes DA, Cooper CW 1974 A comparison of pentagastrin injection and calcium infusion as provocative agents for the detection of medullary carcinoma of the thyroid. J Clin Endocrinol Metab 39:487-495.
139. Melvin KE, Miller HH, Tashjian AH, Jr 1971 Early diagnosis of medullary
140. Gagel RF, Tashjian AH, Jr, Cummings T, Papathanasopoulos N, Kaplan MM, DeLellis RA, Wolfe HJ, Reichlin S 1988 The clinical outcome of prospective screening for multiple endocrine neoplasia type 2a. An 18-year experience. N Engl J Med 318:478-484.
141. Wohllk N, Cote GJ, Bugalho MM, Ordonez N, Evans DB, Goepfert H, Khorana S, Schultz P, Richards CS, Gagel RF 1996 Relevance of RET proto-oncogene mutations in sporadic medullary thyroid carcinoma. J Clin Endocrinol Metab 81:3740-3745.
142. NCCN Oncology Practice Guidelines v.2004. National Comprehensive Cancer Network. NCCN Oncology Practice Guidelines v.2004. www.nccn.org/physician_gls/ f_guidelines.html (Last accessed April 26, 2005).
143. Sobol H, Narod SA, Nakamura Y, Boneu A, Calmettes C, Chaderas D, Charpentier G, Chatal JF, Delepine N, Delisle MJ 1989 Screening for multiple endocrine neoplasia type 2a with DNA-polymorphism analysis. N Engl J Med 321: 996-1001.
144. Shapiro SE, Cote GC, Lee JE, Gagel RF, Evans DB 2003 The role of genetics in the surgical management of familial endocrinopathy syndromes. J Am Coll Surg 197:818-831.
145. Yen TW, Shapiro SE, Gagel RF, Sherman SI, Lee JE, Evans DB 2003 Medullary thyroid carcinoma: results of a standardized surgical approach in a contemporary series of 80 consecutive patients. Surgery 134:890-899; discussion 899-901.
146. Buhr HJ, Kallinowski F, Raue F, Frank-Raue K, Herfarth C 1993 Microsurgical neck dissection for occultly metastasizing medullary thyroid carcinoma. Three-year results. Cancer 72:3685-3693.
147. Wells SA, Jr, Chi DD, Toshima K, Dehner LP, Coffin CM, Dowton SB, Ivanovich JL, DeBenedetti MK, Dilley WG, Moley JF, et al 1994 Predictive DNA testing and prophylactic thyroidectomy in patients at risk for multiple endocrine neoplasia type 2A. Ann Surg 220:237-247; discussion 247-250.
148. Gill JR, Reyes-Mugica M, Iyengar S, Kidd KK, Toulakian RJ, Smith C, Keller MS, Genel M 1996 Early presentation of metastatic medullary carcinoma in multiple endocrine neoplasia, type IIA: Implications for therapy. J Pediatr 129:459-464.
149. Yip L, Lee JE, Shapiro SE, Waguespack SG, Sherman SI, Hoff AO, Gagel RF, Arens JF, Evans DB 2004 Surgical management of hereditary pheochromocytoma. J Am Coll Surg 198:525-534; discussion 534-525.